https://www.zacks.com/stock/news/2200350/3-thrivent-mutual-funds-to-buy-now?cid=CS-ZC-FT-mutual_fund_commentary-2200350
Dec 20, 2023 - Invests in Thrivent mutual funds such as TSCSX, TMSIX and TLVIX for reliable returns.
zc:-7726736028202574971
0
https://www.zacks.com/stock/news/2200363/is-spdr-russell-1000-low-volatility-focus-etf-onev-a-strong-etf-right-now?cid=CS-ZC-FT-smart_beta_etf-2200363
Dec 20, 2023 - Smart Beta ETF report for ONEV
zc:2363114577419607612
0
https://seekingalpha.com/article/4658727-i-was-bearish-on-paypal-but-after-a-77-percent-decline-now-im-buying?source=feed_tag_editors_picks
Dec 19, 2023 -
0
sa:-6602172880321534991
0
https://www.zacks.com/stock/news/2200158/reasons-to-add-allete-ale-to-your-portfolio-right-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2200158
Dec 19, 2023 - ALLETE Inc.'s (ALE) rising earnings estimates, regular dividend payments and a solid investment plan, makes it a strong choice for investment in the utility space.
zc:2480715385205416165
0
https://www.zacks.com/stock/news/2200099/cbt-or-aiquy-which-is-the-better-value-stock-right-now?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_3-2200099
Dec 19, 2023 - CBT vs. AIQUY: Which Stock Is the Better Value Option?
zc:1509626337435394723
0
https://www.zacks.com/stock/news/2200076/reasons-to-retain-danaher-dhr-stock-in-your-portfolio-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2200076
Dec 19, 2023 - Strength in the Life Sciences segment and accretive acquisition bode well for Danaher (DHR). The company's measures to reward its shareholders are encouraging.
zc:6291717266539916574
0
https://www.zacks.com/stock/news/2200058/here-s-why-one-should-retain-american-airlines-aal-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2200058
Dec 19, 2023 - Strong air-travel demand and debt-reduction efforts boost American Airlines (AAL).
zc:-1206396384732075753
0
https://www.zacks.com/stock/news/2200052/here-s-why-you-should-invest-in-penumbra-pen-stock-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2200052
Dec 19, 2023 - Investors are optimistic about Penumbra (PEN), which is led by growth in vascular and neuro businesses.
zc:-8396297506278278322
0
https://www.zacks.com/stock/news/2199982/bears-are-losing-control-over-netease-ntes-here-s-why-it-s-a-buy-now?cid=CS-ZC-FT-tale_of_the_tape|hammer_chart_pattern_(ta)-2199982
Dec 19, 2023 - After losing some value lately, a hammer chart pattern has been formed for NetEase (NTES), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
zc:771546392895407178
0
https://www.zacks.com/stock/news/2199972/here-s-why-you-should-retain-quidelortho-qdel-stock-for-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2199972
Dec 19, 2023 - QuidelOrtho's (QDEL) strong product portfolio raises optimism about the stock.
zc:762280562715709088
0